NCT04297332

Brief Summary

This trial studies the main and interactive effects of episodic future thinking and future thinking priming tasks on helping participants to quit smoking. Episodic future thinking and future thinking priming tasks may decrease delay discounting rates and reduce relapse to smoking and help participants quit smoking.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
26

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2020

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2020

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

February 28, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 5, 2020

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 28, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 28, 2023

Completed
Last Updated

February 8, 2024

Status Verified

February 1, 2024

Enrollment Period

4 years

First QC Date

February 28, 2020

Last Update Submit

February 6, 2024

Conditions

Outcome Measures

Primary Outcomes (2)

  • Change in Delay discounting rate

    Assessed with the 5-Trial Adjusting Delay Discounting.

    Baseline, and 4 and 12 weeks after quit date

  • Latency to relapse

    Will be assessed with the Timeline Follow-Back procedure administered by telephone. Analyzed using generalized mixed models.

    Baseline, assessed up to 12 weeks

Secondary Outcomes (7)

  • Latency to first relapse

    up to 12 weeks

  • Number of days abstinent

    Up to 12 weeks

  • 7-day point prevalence abstinence rates

    At 4 and 12 weeks after quit date

  • Attentional, motor, and non-planning impulsiveness

    Up to 12 weeks

  • Behavioral inhibition and behavioral activation

    Up to 12 weeks

  • +2 more secondary outcomes

Study Arms (4)

Arm I (active EFT, active FTP)

EXPERIMENTAL

Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete an active episodic future thinking or active future thinking priming task once per week for 12 weeks, alternating every week between tasks.

Behavioral: Behavioral InterventionOther: Informational InterventionOther: Telephone-Based Intervention

Arm II (active EFT, control FTP)

EXPERIMENTAL

Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete an active episodic future thinking or control future thinking priming task once per week for 12 weeks, alternating every week between tasks.

Behavioral: Behavioral InterventionOther: Informational InterventionDrug: Nicotine ReplacementOther: Telephone-Based Intervention

Arm III (control EFT, active FTP)

EXPERIMENTAL

Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete a control episodic future thinking or active future thinking priming task once per week for 12 weeks, alternating every week between tasks.

Behavioral: Behavioral InterventionOther: Informational InterventionDrug: Nicotine ReplacementOther: Telephone-Based Intervention

Arm IV (control EFT, control TFP)

ACTIVE COMPARATOR

Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete a control episodic future thinking or control future thinking priming tasks once per week for 12 weeks, alternating every week between tasks.

Behavioral: Behavioral InterventionOther: Informational InterventionDrug: Nicotine ReplacementOther: Telephone-Based Intervention

Interventions

Complete active episodic thinking task

Also known as: Behavior Conditioning Therapy, behavior modification, Behavior or Life Style Modifications, Behavior Therapy, Behavioral Interventions, Behavioral Modification, BEHAVIORAL THERAPY, Behavioral Treatment, Behavioral Treatments
Arm I (active EFT, active FTP)Arm II (active EFT, control FTP)

Provided with Forever Free relapse prevention booklet

Arm I (active EFT, active FTP)Arm II (active EFT, control FTP)Arm III (control EFT, active FTP)Arm IV (control EFT, control TFP)

Receive nicotine patches, gum, or lozenges

Also known as: nicotine replacement therapy, NRT
Arm II (active EFT, control FTP)Arm III (control EFT, active FTP)Arm IV (control EFT, control TFP)

Receive coaching call

Arm I (active EFT, active FTP)Arm II (active EFT, control FTP)Arm III (control EFT, active FTP)Arm IV (control EFT, control TFP)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Smoke \>= 8 cigarettes daily
  • Planning to quit in the next 14 days
  • No regular use of other tobacco products
  • Access to the internet
  • In possession of a smartphone with text messaging capabilities
  • In possession of an email address accessible at least every other day

You may not qualify if:

  • Unable or unwilling to provide consent
  • Unable to provide data to the research team after the quit date
  • Current use of bupropion or varenicline
  • Drinking \>= 20 alcoholic drinks per week
  • Use of drugs of abuse in the past 30 days
  • Living in the same household as a participant already enrolled in this study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Roswell Park Cancer Institute

Buffalo, New York, 14263, United States

Location

MeSH Terms

Interventions

Behavior TherapyNicotine Replacement Therapy

Intervention Hierarchy (Ancestors)

PsychotherapyBehavioral Disciplines and ActivitiesDrug TherapyTherapeutics

Study Officials

  • Christine Sheffer

    Roswell Park Cancer Institute

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 28, 2020

First Posted

March 5, 2020

Study Start

January 1, 2020

Primary Completion

December 28, 2023

Study Completion

December 28, 2023

Last Updated

February 8, 2024

Record last verified: 2024-02

Locations